• 1. 356. Synthetic antimalarials. Part XXXI. 2-p-chloroanilino-4-β-diethylaminoethylaminoquinazolines containing various substituents in the quinazoline nucleus
  F. H. S. Curd,J. K. Landquist,F. L. Rose J. Chem. Soc. 1948 1759
• 2. Formula index
  J. Chem. Soc. 1947 1746

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Recent Advances in the Application of 2,4-Dichloro-7-methoxyquinazoline (CAS 62484-31-5) in Chemical Biology and Pharmaceutical Research

2,4-Dichloro-7-methoxyquinazoline (CAS 62484-31-5) is a versatile chemical intermediate that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This heterocyclic compound serves as a key building block for the synthesis of various biologically active molecules, particularly kinase inhibitors and anticancer agents. Recent studies have highlighted its role in the development of targeted therapies, making it a compound of considerable interest to researchers in the field of chemical biology and pharmaceutical sciences.

One of the most notable applications of 2,4-Dichloro-7-methoxyquinazoline is its use as a precursor in the synthesis of epidermal growth factor receptor (EGFR) inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in the development of novel tyrosine kinase inhibitors (TKIs) with improved selectivity and reduced off-target effects. The researchers utilized this compound to introduce specific functional groups that enhanced binding affinity to mutant forms of EGFR, which are often resistant to conventional therapies. The study reported a significant reduction in tumor growth in preclinical models, suggesting promising therapeutic potential.

In addition to its role in oncology, 2,4-Dichloro-7-methoxyquinazoline has also been investigated for its antimicrobial properties. A recent study in Bioorganic & Medicinal Chemistry Letters explored its derivatives as potential inhibitors of bacterial DNA gyrase, an essential enzyme for bacterial replication. The study identified several derivatives with potent activity against drug-resistant strains of Staphylococcus aureus and Escherichia coli. These findings open new avenues for the development of next-generation antibiotics to combat the growing threat of antimicrobial resistance.

Another area of research where 2,4-Dichloro-7-methoxyquinazoline has shown promise is in the field of neurodegenerative diseases. A 2022 publication in ACS Chemical Neuroscience reported the synthesis of quinazoline-based compounds that exhibited neuroprotective effects in models of Alzheimer's disease. The researchers attributed these effects to the compound's ability to modulate key signaling pathways involved in neuronal survival and inflammation. This study underscores the potential of 2,4-Dichloro-7-methoxyquinazoline as a scaffold for designing multifunctional agents targeting complex diseases.

Despite its promising applications, challenges remain in the optimization of 2,4-Dichloro-7-methoxyquinazoline-based compounds. Issues such as bioavailability, metabolic stability, and toxicity need to be addressed to facilitate their transition from bench to bedside. Recent advances in computational chemistry and structure-activity relationship (SAR) studies have provided valuable insights into overcoming these hurdles. For instance, a 2023 study in the European Journal of Medicinal Chemistry employed molecular docking and dynamics simulations to predict the pharmacokinetic properties of novel derivatives, leading to the identification of candidates with improved drug-like characteristics.

In conclusion, 2,4-Dichloro-7-methoxyquinazoline (CAS 62484-31-5) continues to be a focal point of research in chemical biology and pharmaceutical sciences. Its versatility as a synthetic intermediate and its potential to yield biologically active compounds make it an invaluable tool for drug discovery. Ongoing studies are expected to further elucidate its mechanisms of action and expand its applications, paving the way for innovative therapeutic strategies. Researchers are encouraged to explore its derivatives and optimize their properties to harness their full potential in addressing unmet medical needs.

• 13790-39-1(4-chloro-6,7-dimethoxy-quinazoline)
• 105763-77-7(2,4-Dichloro-6-methoxyquinazoline)
• 1160994-83-1(2,4-Dichloro-7-(trifluoromethoxy)quinazoline)
• 61948-60-5(2,4-Dichloro-8-methoxyquinazoline)
• 55496-52-1(4-Chloro-7-methoxyquinazoline)
• 27631-29-4(2,4-Dichloro-6,7-dimethoxyquinazoline)
• 62484-33-7(Quinazoline, 2,4-dichloro-7-propoxy-)
• 62484-32-6(Quinazoline, 2,4-dichloro-7-ethoxy-6-methoxy-)
• 61948-59-2(2,4-Dichloro-5-methoxyquinazoline)
• 50424-28-7(4-Chloro-6-methoxyquinazoline)